AR050673A1 - Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno - Google Patents

Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno

Info

Publication number
AR050673A1
AR050673A1 ARP050102648A ARP050102648A AR050673A1 AR 050673 A1 AR050673 A1 AR 050673A1 AR P050102648 A ARP050102648 A AR P050102648A AR P050102648 A ARP050102648 A AR P050102648A AR 050673 A1 AR050673 A1 AR 050673A1
Authority
AR
Argentina
Prior art keywords
knee
pain
compression
treatment
nerve
Prior art date
Application number
ARP050102648A
Other languages
English (en)
Inventor
Kang Ahn
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Publication of AR050673A1 publication Critical patent/AR050673A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica compuesta por toxina botulínica y un portador farmacologicamente aceptable para el tratamiento del dolor en la articulacion de la rodilla, causado por el atrapamiento o la compresion del nervio safeno. La composicion de la presente es para aplicacion por inyeccion subcutánea, arriba de la cara medial de la rodilla.
ARP050102648A 2004-06-28 2005-06-27 Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno AR050673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040048889A KR100668570B1 (ko) 2004-06-28 2004-06-28 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물

Publications (1)

Publication Number Publication Date
AR050673A1 true AR050673A1 (es) 2006-11-15

Family

ID=35782045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102648A AR050673A1 (es) 2004-06-28 2005-06-27 Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno

Country Status (12)

Country Link
US (2) US20080199497A1 (es)
EP (1) EP1771195B1 (es)
JP (1) JP4933429B2 (es)
KR (1) KR100668570B1 (es)
AR (1) AR050673A1 (es)
CA (1) CA2571415C (es)
DK (1) DK1771195T3 (es)
ES (1) ES2625128T3 (es)
HU (1) HUE033364T2 (es)
PL (1) PL1771195T3 (es)
PT (1) PT1771195T (es)
WO (1) WO2006001676A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2016002984A1 (ko) * 2014-06-30 2016-01-07 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
EP1487481A4 (en) * 2002-03-01 2005-11-23 Elan Pharm Inc METHOD FOR TREATING NERVE TERMINATION SYNDROMES
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof

Also Published As

Publication number Publication date
ES2625128T3 (es) 2017-07-18
US8337862B2 (en) 2012-12-25
HUE033364T2 (en) 2017-11-28
US20090317426A1 (en) 2009-12-24
US20080199497A1 (en) 2008-08-21
EP1771195B1 (en) 2017-03-01
WO2006001676A1 (en) 2006-01-05
JP4933429B2 (ja) 2012-05-16
EP1771195A1 (en) 2007-04-11
KR20060000043A (ko) 2006-01-06
CA2571415A1 (en) 2006-01-05
PL1771195T3 (pl) 2017-08-31
DK1771195T3 (en) 2017-05-15
CA2571415C (en) 2016-10-04
JP2008504364A (ja) 2008-02-14
EP1771195A4 (en) 2010-08-18
PT1771195T (pt) 2017-06-05
KR100668570B1 (ko) 2007-01-16

Similar Documents

Publication Publication Date Title
DK1521593T3 (da) Transdermale botulinumtoksinforbindelser
CA2424242A1 (en) Methods for treating muscle injuries
BRPI0508440A (pt) composições e métodos para diagnóstico tópico e transporte terapêutico
AR050673A1 (es) Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno
PE20120206A1 (es) Variantes de polipeptidos receptores de activina iib
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2011154126A3 (en) Skin antiaging treatment
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
MX2009003737A (es) Composicion inyectable en deposito y su procedimiento de preparacion.
PT1280541E (pt) Utilizacao de estirpes acetogenicas hidrogenotroficas para a prevencao ou o tratamento de disturbios digestivos
NZ700623A (en) Botulinum toxin dosage regimen for chronic migraine prophylaxis
BR112014007675A2 (pt) tratamento de doença articular degenerativa
BR0307496A (pt) Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
AR062775A1 (es) Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
Reebye et al. Module 2: Nonsurgical management of spasticity
AR048811A1 (es) Uso de toxina botulinica en la preparacion de un medicamento para evitar el crecimiento del vello
ATE410448T1 (de) Neues peptid und pharmazeutische zusammensetzung, die dieses peptid enthält
WO2023285686A3 (en) Recombinant variants of r-spondin proteins and their use
ES2571792T3 (es) Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal